Improve metabolic health without sacrificing muscle
En los laboratorios del Instituto Karolinska de Estocolmo, investigadores suecos han desarrollado una pastilla experimental que activa el metabolismo muscular para regular el azúcar en sangre y quemar grasa, sin suprimir el apetito ni provocar los efectos secundarios que acompañan a los tratamientos inyectables actuales. La distinción es filosóficamente relevante: en lugar de restarle al cuerpo —quitándole el deseo de comer—, este enfoque le suma, estimulando la propia maquinaria del músculo. En un momento en que millones de personas gestionan la diabetes y la obesidad como condiciones crónicas de por vida, la posibilidad de preservar la masa muscular mientras se pierde peso representa algo más que un avance clínico: es una reconfiguración de lo que significa tratar el cuerpo con respeto.
- Los tratamientos inyectables como Ozempic dominan el mercado, pero su mecanismo —suprimir el apetito— conlleva pérdida muscular y efectos digestivos que muchos pacientes no toleran a largo plazo.
- El nuevo compuesto beta-2 agonista activa directamente el metabolismo del músculo esquelético, evitando la sobreestimulación cardíaca que había frustrado décadas de investigación en esta clase de fármacos.
- Una primera fase de ensayos clínicos con 73 participantes —48 sin diabetes y 25 con diabetes tipo 2— mostró buena tolerancia y mejoras en la composición corporal sin pérdida de masa muscular.
- El formato en pastilla, frente a la inyección, no es un detalle menor: para pacientes que llevan años con agujas, la simplicidad puede ser el factor que determine si siguen o abandonan el tratamiento.
- La fase II, liderada por la empresa Atrogi AB, determinará si estos resultados se sostienen en poblaciones más amplias y diversas, y si el fármaco puede combinarse con terapias existentes para ampliar sus beneficios.
En el Instituto Karolinska de Estocolmo, un equipo de investigadores lleva años trabajando en una pregunta que la medicina moderna no ha sabido responder del todo bien: cómo tratar la diabetes y la obesidad sin que el remedio resulte tan costoso como la enfermedad. Su respuesta, por ahora experimental, viene en forma de pastilla.
A diferencia de los fármacos inyectables que han acaparado la atención en los últimos años, este nuevo compuesto no actúa suprimiendo el apetito. En cambio, activa el metabolismo del músculo esquelético, lo que permite quemar calorías preservando el tejido muscular. Para quienes gestionan la diabetes o la obesidad durante décadas, esa diferencia es crucial: perder músculo mientras se pierde peso es un intercambio que deteriora la salud a largo plazo.
El fármaco pertenece a una clase conocida como agonistas beta-2, estudiada durante décadas pero nunca perfeccionada para este fin. El obstáculo histórico era claro: estimular el músculo sin sobrecargar el corazón. Los investigadores suecos afirman haberlo resuelto. Los estudios en animales mostraron mejoras en la composición corporal y en la regulación del azúcar sin los problemas digestivos asociados a los tratamientos GLP-1, lo que abrió el camino a los ensayos en humanos.
La primera fase incluyó a 73 personas y los resultados fueron alentadores: buena tolerancia en todos los participantes y ninguna pérdida de masa muscular. El profesor Tore Bengtsson subrayó que el objetivo es mejorar la salud metabólica sin sacrificar músculo. El profesor Shane C. Wright añadió otro argumento a favor: es una pastilla, no una inyección, y esa sencillez importa para los pacientes que llevan años enfrentando agujas.
Lo que hace especialmente prometedor este desarrollo es su flexibilidad potencial. Al actuar por un mecanismo distinto al de los fármacos GLP-1, podría usarse solo o en combinación con tratamientos existentes. La fase II de ensayos clínicos, a cargo de Atrogi AB, será la prueba decisiva: determinar si los beneficios observados se sostienen en poblaciones más amplias con diabetes tipo 2 u obesidad. Los resultados tempranos no siempre se confirman a mayor escala, pero si este lo hace, podría ofrecer a los pacientes un camino genuinamente distinto: perder peso sin perder fuerza.
At the Karolinska Institutet in Stockholm, a team of researchers has been working on a problem that has vexed medicine for years: how to treat diabetes and obesity without the side effects that come with most modern drugs. They believe they may have found an answer, and it comes in pill form.
The experimental medication works differently from the injectable treatments that have dominated recent headlines. Rather than suppressing appetite—the mechanism behind drugs like Ozempic—this new compound activates the metabolism of skeletal muscle itself. The distinction matters. When you burn calories through muscle activity rather than by eating less, you preserve the very tissue that keeps your body functioning well as you age. That preservation of muscle mass is something the researchers consider vital, especially for people managing diabetes or obesity over the long term.
The drug is a beta-2 agonist, a class of compound that has been studied for decades but never quite perfected for this purpose. The challenge has always been the same: activate muscle tissue without overstimulating the heart. The Swedish team says they have solved that problem. In early animal studies, the medication improved body composition and blood sugar regulation while avoiding the digestive problems and appetite loss that plague existing GLP-1 treatments. Those results were promising enough to move to human trials.
The first phase of human testing involved 73 people: 48 without diabetes and 25 with type 2 diabetes. All tolerated the medication well. Tore Bengtsson, a professor at the Wenner-Gren Institute, described the implications this way: the goal is to improve metabolic health without sacrificing muscle, something that matters for both diabetes and obesity patients. Shane C. Wright, an assistant professor at Karolinska's Department of Physiology and Pharmacology, emphasized another advantage—this is a pill, not an injection. For patients who have grown weary of needles, that simplicity carries real weight.
What makes this work particularly intriguing is its potential flexibility. Because the mechanism is different from GLP-1 drugs, the new pill might work on its own or be combined with existing treatments. That opens possibilities that single-drug approaches cannot offer. The researchers also noted that the pill could enable weight loss without the need for injections, a practical benefit that could change how people approach their treatment.
The next step is a phase II clinical trial, led by Atrogi AB, the company developing the drug. This trial will test whether the benefits seen in animals and in the small initial human group actually translate to people living with type 2 diabetes or obesity. That is the crucial test. Promising early results do not always hold up when you move to larger, more diverse populations. But if this one does, it could offer patients a genuinely different path forward—one that lets them lose weight while keeping their strength.
Notable Quotes
Our results point toward a future where we can improve metabolic health without losing muscle mass, which is vital for both type 2 diabetes and obesity patients.— Tore Bengtsson, professor at the Wenner-Gren Institute
This medication represents a new type of treatment with significant potential for type 2 diabetes and obesity patients, enabling healthy weight loss without injections.— Shane C. Wright, assistant professor at Karolinska Institutet's Department of Physiology and Pharmacology
The Hearth Conversation Another angle on the story
Why does it matter that this is a pill instead of an injection? Isn't the mechanism what counts?
The mechanism absolutely counts. But access and adherence matter too. Some people skip doses because they dread the needle. A pill removes that barrier. For a chronic disease you manage for decades, that friction adds up.
The source mentions this could work alongside GLP-1 drugs. What does that combination actually do?
It opens a door. If you use a GLP-1 drug to suppress appetite and this pill to burn fat through muscle, you're hitting the problem from two angles at once. But that's still theoretical. Phase II will tell us if it's safe and effective in real patients.
The researchers seem careful not to oversell this. Why?
Because they've seen hype before. Beta-2 agonists have been studied for years. What's different here is they claim to have solved the heart problem—the thing that stopped these drugs in the past. But that claim needs proof in larger trials before anyone celebrates.
What happens to muscle mass with current diabetes drugs?
That's the real problem. When you lose weight by suppressing appetite, your body often burns muscle along with fat. You end up lighter but weaker. For an older person, that's dangerous. This pill is designed to flip that—burn fat, keep muscle. If it works, that's genuinely new.
How long until patients might actually use this?
Phase II is next. If that succeeds, phase III comes after—larger trials, more diverse patients. Then regulatory approval. Realistically, we're talking years, not months. But the pathway is clear now.